HTA in Turkey Dr Rabia Kahveci 3/19/2018 International Meeting for HTAEmerging Countries
• Health Transformation Program • The Need for HTA in Turkey • The Future of HTA in Turkey International Meeting for HTAEmerging Countries
Health Transformation Programme Since 2003 Objective to make the health system more effective by improving governance, efficiency, user and provider satisfaction and long term fiscal sustainability Key elements include: Implementing Universal Health Insurance, a single Social Security Institute, expanding the delivery of health care and making it more easily accessible and friendly, implementing rational drug use and management of medical materials and devices International Meeting for HTAEmerging Countries
Health Transformation Programme 2003. . total quality management, performance based payments 2004. . Reimbursement Commission under Ministry of Finance 2004. . reference pricing 2005. . Regulations on licencing of pharmaceuticals 2006. . Pharmaceutical expenditure tracking system under SSI and MEDULA initiated 2007. . new health budget law adopted 2008. . mandatory pharmacoeconomic analysis in industry submissions for coverage 3/19/2018 International Meeting for HTAEmerging Countries
In the first three years of the program although health expenditures rose rapidly, increases in both total and public spending on health care seem to have remained affordable because economic growth in Turkey was also rapid. 3/19/2018 International Meeting for HTAEmerging Countries
Health care expenditures 3/19/2018 International Meeting for HTAEmerging Countries
Pharmaceutical expenditures 3/19/2018 International Meeting for HTAEmerging Countries
International Meeting for HTAEmerging Countries
International Meeting for HTAEmerging Countries
With the reforms we have: Increased access to health care (and the technology) Rising expectations …rising health care expenditures, decreased pharmaceutical prices. . high GDP growth rate. . still affordable. . but economical crisis? Future GDP growth? ………. . industry’s focus and investments on emerging countries …………. the need for more attention and regulations Value of money…what is worth paying? 3/19/2018 International Meeting for HTAEmerging Countries
IMS Global Pharmaceutical and Therapy Forecast™ released in October, 2008 The global pharmaceutical market is expected to grow 4. 5 5. 5 percent next year, a pace similar to 2008 sustained double-digit growth in key emerging countries tempered by a slower pace in more established markets 2009 will reflect the new shape of the global pharmaceutical market The market will continue to contend with a number of forces – among them, the shift in growth from developed countries to emerging ones, ………… 3/19/2018 International Meeting for HTAEmerging Countries
In Europe, growth driven by the continued aging of the region’s population and rising demand for preventive care will be tempered by the increased impact of health technology assessments, ………. . 3/19/2018 International Meeting for HTAEmerging Countries
The pharmerging markets of China, Brazil, India, South Korea, Mexico, Turkey and Russia are forecast to grow at a combined 14 - 15 percent pace to $105 - $115 billion. Along with the pharmaceutical industry’s increased focus on these high-growth markets, these countries are benefiting from greater government spending on healthcare and broader public and private healthcare funding – which is driving greater access to, and demand for, innovative medicines. “Biopharmaceutical companies can still find avenues of growth by focusing on emerging markets, …’’ 3/19/2018 International Meeting for HTAEmerging Countries
The Need for HTA cost-effective use, cost-effective prescribing Rational drug prescribing/use Clinical Practice Guidelines 3/19/2018 International Meeting for HTAEmerging Countries
Focus on Communication Collaboration Networking Capacity building Adaptation Structuring. . where? how? Who? 3/19/2018 International Meeting for HTAEmerging Countries
STRENGTHS WEAKNESSES Individuals skilled and trained in HTA related fields International relations; WB and EU Recent reforms in health care; investments for information network and databank Good examples of evidence based decisionmaking Poor multidisciplinary approach, poor communication between stakeholders Traditional “expert-based” decisionmaking Poor availability of data Poor quality of data Poor priority setting process Lack of general awareness of HTA Lack of interest by universities Lack of trained human resources Poor information technology OPPORTUNITIES THREATS Demand for transparency in decisionmaking Funding Demand for evidence and demand for Political instability credibility by decisionmakers “New and expensive” is good belief Interest of mass media in health care reforms Not a priority in current reforms Overwhelming demand for new technologies Recent big national investments could requires evaluation challenge resources Current health care reforms; restructuring of Possible resistance for use by decisionmakers health care, general health insurance International Meeting for HTA 3/19/2018 Emerging Countries Opportunity to engage politicians’ interest
Thank you 3/19/2018 International Meeting for HTAEmerging Countries
Скачать презентацию HTA in Turkey Dr Rabia Kahveci 3 19 2018 International
320723f4fcfddb8b8d359cd69b2bbccc.ppt